[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-male-and-female-subjects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-male-and-female-subjects":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,86,112,136,162,182,227,251],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100637642","phase-1-pharmacokinetics-of-y-4-tablets-with-pregabalin-capsules-and-riluzole-tablets-in-us-healthy-participants-100637642",false,"NCT07618715","Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants","An Open-label, Single-dose, Three-period Phase Ⅰ Study to Compare the Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants","Inclusion Criteria:\n\n1. Healthy adult male and female participants, 18-45 years of age (including both ends).\n2. Body weight ≥ 50 kg for male and ≥ 45 kg for female, body mass index (BMI) within the range of 19 - 28 kg\u002Fm2 (including both ends).\n3. During the screening period, serum creatinine is within the normal range, or the standard creatinine clearance (CLcr) estimated by Cockcroft-Gault formula is ≥ 80 mL\u002Fmin (for female participant, according to the calculation result × 0.85）\n4. Participants who are able to understand and give their signed informed consent before any trial related procedures are performed.\n\nExclusion Criteria:\n\n1. Participants who are known to be allergic to pregabalin, riluzole or any excipients of Y-4 tablets (microcrystalline cellulose, copovidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, Opadry amb Ⅱ), have allergic diseases or allergic constitution;\n2. Participants who have special requirements for diet and cannot follow the unified diet;\n3. Physical examinations, vital signs, 12-lead electrocardiograms (ECG), laboratory tests (Hematology, serum chemistry, coagulation test, urinalysis, etc.) and other screening tests found abnormalities that the researchers judged to be of clinical significance;\n4. Participants who have experienced angioedema in the past (such as swelling of the face, mouth (tongue, lips, and gums), and neck (pharynx and throat));\n5. History of dizziness or vertigo with clinical significance, or disease of inner ear known to cause dizziness or vertigo;\n6. QTcF \\> 450 msec at the screening stage (Corrected using Fridericia's formula: QTcF = QT \u002F(RR\\^0.33), where RR = 60 \u002F heart rate);\n7. Diagnosed with insomnia, anxiety disorder, depression, epilepsy, or other serious mental disorders, and principal investigator determines that the participant is not suitable to participate in this trial;\n8. Presence or history of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of medicines, participants who have impaired hepatic function at the time of screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 1.5 ULN; or total bilirubin (TBIL) \\> 1.0 ULN;\n9. Participants who drink too much tea, coffee and\u002For caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months prior to screening, or disagree that any caffeine-containing beverages are prohibited during the trial;\n10. Participants who have consume any diet (food or beverage) rich in grapefruit, pitaya, mango and cranberry within 14 days prior to screening;\n11. Participants have disease history or current disease that may affect the safety evaluation of the participant or the internal process of the study drug, including the central nervous system, cardiovascular system, digestive system, endocrine system, respiratory system, urinary system, hematological system, immunology, psychiatry, metabolic abnormalities, gastrointestinal surgery (excluding appendicitis surgery), etc. In particular, there is a history of dysphagia or any gastrointestinal disease affecting drug absorption (including frequent nausea or vomiting caused by any cause) and eye diseases;\n12. Donation or loss of blood equal to or in excess of 400 mL, or blood transfusion within 3 months prior to screening; or donation or loss of blood equal to or in excess of 200 mL within 1 month prior to screening;\n13. Participants who have taken any drugs known to be strong inhibitors or inducers of cytochrome P450 enzymes within 2 months prior to screening (such as inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors - serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines); or participants who have taken any prescription drugs, over-the-counter drugs and traditional Chinese medicine or herbal medicine other than the above drugs within 14 days prior to screening;\n14. Participants who have taken central nervous system (CNS) depressants including opioids (pethidine hydrochloride, morphine, dihydromorphine hydrochloride, fentanyl, Tramadol, etc), benzodiazepines (diazepam, flurazepam, clonazepam, oxazepam, chlordiazepine and triazolam etc), antiepileptic drugs (carbamazepine, sodium valproate, phenobarbital drugs etc) within 2 months prior to screening;\n15. Participant with sleep apnea, or participants with severe sleep snoring and daytime drowsiness;\n16. Participants with history of neuropsychiatric disorders, including current or past history of mental illness, suicidal ideation based on the C-SSRS score of 1 or higher;\n17. Participant participated in any other clinical trials within 3 months prior to screening;\n18. Current or former drug users, or positive urine screen for drugs of abuse at screening (screening items include: Opiates, Amphetamines, Cocaine, Cannabinoids, Barbiturates, Benzodiazepines);\n19. Alcoholics or regular drinkers within 3 months prior to screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol with 40% alcohol content or 150 mL of wine), or whose alcohol breath test results are greater than 0.0 mg\u002F100 mL, or who cannot abstain from alcohol during the trial;\n20. Smokers or those who cannot comply with the prohibition of smoking during the trial, or positive for cotinine screening;\n21. Participants who is positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, syphilis antibody or human immunodeficiency virus (HIV) antibody;\n22. Male participants (or their partners) or female participants have baby plans during the whole trial period and within 3 months after the end of the trail, or participants are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, condoms, ligation, etc.) during the trial period.\n23. Female participants who have unprotected intercourse within 14 days prior to screening, or pregnant or lactating women;\n24. Participants with poor compliance or other factors unsuitable for participation in this trial.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},11,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The primary goal of this clinical trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules and riluzole tablets in the US healthy adult participants after single oral administration under fasted condition.\n\nThe secondary goal of the trial is to evaluate the safety and tolerability of Y-4 tablets, pregabalin capsules and riluzole tablets in the US healthy adult participants.",[28],"Healthy Male and Female Subjects",[30,31,32],"Phase Ⅰ","Y-4 Tablet","Postherpetic Neuralgia","NOT_YET_RECRUITING","2026-05-24",{"date":36,"type":37},"2026-06-01","ACTUAL",{"date":39,"type":22},"2026-06-30",{"date":41,"type":22},"2026-10-31",{"name":43,"class":44},"Neurodawn Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":45},"100604054","nicotinamide-mononucleotide-supplementation-for-exercise-tolerance-improvement-in-healthy-older-adults-100604054","NCT07144527","Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","Inclusion Criteria:\n\n* Adults aged 60 to 80 years, of any sex\n* Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study\n* Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing\n* Montreal Cognitive Assessment (MoCA) score of 26 or higher\n* Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation\n* Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling\n* Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications\n* Ability to attend at least four in-person laboratory visits in Beverly Hills, California\n* Non-smoker for at least 12 months\n* Able to provide informed consent and comply with study procedures\n* Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study\n\nExclusion Criteria:\n\n* Severe cardiovascular disease (e.g., recent myocardial infarction \\\u003C6 months, unstable angina, uncontrolled hypertension \\>160\u002F100 mmHg)\n* Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)\n* Significant neurological impairments that hinder comprehension of instructions or participation in exercise\n* Terminal illness or conditions limiting life expectancy or ability to complete the study\n* Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions\n* Significant orthopedic limitations or injuries that prevent safe exercise participation\n* Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks\n* Anticipated or current alcohol consumption \\>2 drinks per week, or unwillingness to abstain from alcohol during the study\n* Current substance abuse affecting study participation or adherence\n* Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives\n* Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion\n* Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results","60 Years","80 Years",{"count":55,"type":22},40,[57],"NA","This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.\n\nThe primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.\n\nEGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.",[60,61,62,28],"Aging","Frailty","Exercise Tolerance",[64,65,62,60,66,67,68,69,70,71,72,73,74],"Nicotinamide Mononucleotide","NAD+ Metabolism","Older Adults","Betaine","Hydrogen Peroxide (low-dose, dietary)","High Intensity Interval Training","VO2peak","Lactate Threshold","Critical Power","Anaerobic Work Capacity","Healthy Volunteers","RECRUITING","2026-02-19",{"date":78,"type":37},"2026-02-20",{"date":80,"type":22},"2026-02-21",{"date":82,"type":22},"2027-01-01",{"name":84,"class":85},"Scott Silveira","OTHER",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100579520","near-infrared-spectroscopy-of-auricular-stimulation-100579520","NCT06825364","Near-InfraRed Spectroscopy of Auricular Stimulation","Neural Responses to Tactile Auricular Stimulation Measured by Functional Near-infrared Spectroscopy in Pain-free Volunteers","NIRAS","Inclusion Criteria:\n\nAge of at least 18 years\n\nExclusion Criteria:\n\n1. frequent or chronic pain requiring the use of pain-relieving medications more than twice per week, on average, in the last 3 months,\n2. history or symptoms of neuropathy,\n3. active lesions or skin disruptions to either ear,\n4. recent (\\\u003C 3 mo) illicit drug use,\n5. history of substance misuse\u002Fabuse,\n6. current or recent (\\\u003C1 month) opioid or marijuana use, and\n7. current regular use of psychoactive prescription medications",{"count":95,"type":22},80,[57],"This is a single-visit non-invasive study of healthy volunteer subjects. Brain activity will be measured with infra-red light sensors attached to a cap worn on the head, while both ears are gently stimulated with plastic filaments.",[28,99],"Healthy Volunteer Study",[101,102],"auricular stimulation","functional near infrared spectroscopy","2026-02-13",{"date":105,"type":37},"2026-02-18",{"date":107,"type":37},"2025-08-12",{"date":109,"type":22},"2028-02-01",{"name":111,"class":85},"University of Pittsburgh",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":45},"100594002","phase-1-to-evaluate-the-effect-of-food-on-the-pharmacokinetics-of-y-4-tablets-in-healthy-subjects-100594002","NCT07013773","To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects","A Randomized, Open-label, Single-dose, Two-period, Crossover Phase I Clinical Trial With Two Parallel Arms Evaluating the Impact of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects","Y-4-LC-03","Inclusion Criteria:\n\n1. Healthy adult male and female subjects, 18-45 years of age (including both ends).\n2. Body weight ≥ 50 kg for male and ≥ 45 kg for female, body mass index (BMI) within the range of 19 - 28 kg\u002Fm2 (including both ends).\n3. During the screening period, serum creatinine is within the normal range, or the standard creatinine clearance (CLcr) estimated by Cockcroft-Gault formula is ≥ 80 mL\u002Fmin (for female subject, according to the calculation result × 0.85）.\n4. Subjects who are able to understand and give their signed informed consent before any trial related procedures are performed.\n\nExclusion Criteria:\n\n1. Subjects who are known to be allergic to pregabalin, riluzole or any excipients of Y-4 tablets (microcrystalline cellulose, Copovidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry amb Ⅱ), have allergic diseases or allergic constitution;\n2. Subjects who have special requirements for diet and cannot follow the unified diet;\n3. Physical examinations, vital signs, 12-lead electrocardiograms (ECG), chest X-ray (front position), laboratory tests (hematology, serum chemistry, coagulation test, urinalysis, etc.) and other screening tests found abnormalities that the researchers judged to be of clinical significance;\n4. Subjects who have experienced angioedema in the past (such as swelling of the face, mouth (tongue, lips, and gums), and neck (pharynx and throat));\n5. History of dizziness or vertigo with clinical significance, or disease of inner ear known to cause dizziness or vertigo;\n6. QTcF \\> 450 msec at the screening stage;\n7. Diagnosed with insomnia, anxiety disorder, depression, epilepsy, or other serious mental disorders, and principal investigator determines that the subject is not suitable to participate in this trial;\n8. Presence or history of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of medicines;\n9. Subjects who drink too much tea, coffee and\u002For caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months prior to screening, or disagree that any caffeine-containing beverages are prohibited during the trial;\n10. Subjects who have consume any diet (food or beverage) rich in grapefruit, pitaya, mango and cranberry within 14 days prior to screening;\n11. Subjects have disease history or current disease that may affect the safety evaluation of the subject or the internal process of the study drug, including the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, immunology, psychiatry, metabolic abnormalities, gastrointestinal surgery (excluding appendicitis surgery), etc. In particular, there is a history of dysphagia or any gastrointestinal disease affecting drug absorption (including frequent nausea or vomiting caused by any cause) and eye diseases;\n12. Donation or loss of blood equal to or in excess of 400 mL, or blood transfusion within 3 months prior to screening; or donation or loss of blood equal to or in excess of 200 mL within 1 month prior to screening;\n13. Subjects who have taken any drugs known to be strong inhibitors or inducers of cytochrome P450 enzymes within 2 months prior to screening (such as inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors - serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines); or subjects who have taken any prescription drugs, over-the-counter drugs and Chinese herbal medicine other than the above drugs within 14 days prior to screening;\n14. Subjects who have taken central nervous system (CNS) depressants including opioids (pethidine hydrochloride, morphine, dihydromorphine hydrochloride, fentanyl, tramadol, etc), benzodiazepines (diazepam, flurazepam, clonazepam, oxazepam, chlordiazepine and triazolam etc), antiepileptic drugs (carbamazepine, sodium valproate, phenobarbital drugs etc) within 2 months prior to screening;\n15. Subject with sleep apnea, or subjects with severe sleep snoring and daytime drowsiness;\n16. Subjects with suicidal thoughts and behavior;\n17. Subject participated in any other clinical trials within 3 months prior to screening;\n18. Current or former drug users, or positive urine screen for drugs of abuse at screening (screening items include: dimethylenedioxyamphetamine, methamphetamine, ketamine, morphine, tetrahydrocannabinoid acid, cocaine);\n19. Alcoholics or regular drinkers within 3 months prior to screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol with 40% alcohol content or 150 mL of wine), or whose alcohol breath test results are greater than 0.0 mg\u002F100 mL, or who cannot abstain from alcohol during the trial;\n20. Smokers or those who cannot comply with the prohibition of smoking during the trial, or positive for cotinine screening;\n21. Subjects who is positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, syphilis antibody or human immunodeficiency virus (HIV) antibody;\n22. Male subjects (or their partners) or female subjects have baby plans during the whole trial period and within 3 months after the end of the trial, or subjects are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, condoms, ligation, etc.) during the trial period;\n23. Female subjects who have unprotected intercourse within 14 days prior to screening, or pregnant or lactating women;\n24. Subjects with poor compliance or other factors unsuitable for participation in this trial.",{"count":121,"type":22},20,[25],"Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole.\n\nThe objective is to assess the effect of food on the pharmacokinetics (PK) of pregabalin and riluzole in healthy adult subjects after a single oral dose of Y-4 tablets.",[28],[126],"phase I trial","2025-06-06",{"date":129,"type":37},"2025-06-10",{"date":131,"type":37},"2025-05-19",{"date":133,"type":22},"2025-07",{"name":135,"class":85},"Beijing Tiantan Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":45},"100590961","phase-1-validation-study-of-an-assistive-pulse-data-collection-device-100590961","NCT06974227","Validation Study of an Assistive Pulse Data Collection Device","Inclusion Criteria:\n\n1. Age 18-65 years\n2. BMI 18.5-22.5 kg\u002Fm2\n3. Willing to give informed consent\n\nExclusion Criteria:\n\n1\\. dorsally located radial artery","65 Years",{"count":144,"type":22},30,[25],"Background: Traditional Chinese Medicine (TCM) relies on pulse diagnosis, a subjective and complex method that is crucial for assessing patients' health status. The COVID-19 pandemic has disrupted healthcare delivery, highlighting the need for remote diagnostic tools. To address this, an Assistive Pulse Data Collection Device (APDC) has been developed to capture and regenerate pulse features for remote pulse assessment in TCM.\n\nObjective: This study aims to validate the accuracy and reliability of the APDC by assessing its agreement with Chinese Medicine Practitioners (CMPs) and collecting users' feedback.\n\nIntervention: The APDC consists of a radial artery viewing device, pulse collection device, and pulse regeneration device.\n\nMethods: Subjects will be recruited via social media and posters at the University. Inclusion criteria include age 18-65 years and BMI 18.5-22.5 kg\u002Fm2, while exclusion criteria include a dorsally located radial artery. Registered CMPs with at least 5 years of clinical experience will assess the pulse from both participants and the regenerated pulse by the device.\n\nOutcome Assessment: Agreement in pulse features between the subjects' real pulse and the pulse regeneration device will be assessed using a self-developed questionnaire, covering frequency, rhythm, wideness, and force. Quantitative and qualitative feedback from subjects and CMPs will be collected to assess their views on the APDC Device in terms of satisfaction, ease of use, and comfortability.",[28],[149,150,151,152],"machine","pulse","wave form","TCM","2025-05-08",{"date":155,"type":37},"2025-05-15",{"date":157,"type":37},"2025-03-20",{"date":159,"type":22},"2025-07-31",{"name":161,"class":85},"The Hong Kong Polytechnic University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":45},"100588002","phase-1-pharmacokinetics-of-y-4-tablets-with-pregabalin-capsules-and-riluzole-tablets-in-chinese-healthy-subject-100588002","NCT06935721","Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject","An Open-label, Single-dose, Three-period Phase 1 Study to Compare the Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Healthy Subjects Under Fasted Condition",{"count":169,"type":22},10,[25],"Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole.\n\nThe objective of the trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules (Lyrica®) and riluzole tablets (Rilutek®) in Chinese healthy adult subjects after single oral administration under fasted condition.",[28],[126],"2025-04-13",{"date":176,"type":37},"2025-04-20",{"date":178,"type":37},"2025-03-28",{"date":180,"type":22},"2025-06",{"name":135,"class":85},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":16,"sex":17,"minAge":189,"maxAge":142,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":200,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":45},"100578956","avocado-and-postprandial-responses-100578956","NCT06818032","Avocado and Postprandial Responses","Acute Avocado Consumption on Postprandial Glycemic and Appetite\u002FSatiety Responses","Inclusion Criteria:\n\n* Biological sex males or females\n* Age 21 to 65 years\n* BMI between 18.5 and 34.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Actively pregnant or lactating women\n* Diagnosis of prediabetes or diabetes (fasting glucose \\>100 mg\u002FdL)\n* Current diagnosis of uncontrolled hypertension (systolic BP: \\>160 mmHg, diastolic BP: \\>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month\n* Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \\>200 mg\u002FdL, fasting triglycerides \\>200 mg\u002FdL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month\n* Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus)\n* History of bariatric or certain other surgeries related to weight control\n* Any medication used to lower blood glucose\u002Fantidiabetic medications \\[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\\] as well as medications affecting weight, appetite\u002Fhunger or gut motility.\n* Smoking or use of other tobacco products (during 6 months prior to the start of the study)\n* Antibiotic use during the intervention or for 3 weeks prior to any treatment period\n* History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets)\n* Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence\n* Body weight loss of \\>10% within the last 6 months prior to study start\n* Unable or unwilling to give informed consent or communicate with study staff\n* Self-report of alcohol or substance abuse within the past 12 months and\u002For current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)\n* Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol\n* Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.","21 Years",{"count":144,"type":22},[57],"The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating.\n\nThe investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:\n\n1. Whole-wheat bread and strawberry jam\n2. Whole-wheat bread, strawberry jam, and avocado\n3. Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)\n\nParticipants will undergo 3 test periods, each separated by a week. Each test period consists of one day with set meals that the investigators will provide (breakfast, lunch, and dinner), and then the next morning, participants will eat a breakfast meal and have blood drawn several times over 4 hours.",[194,195,74,196,28,197,198,199],"Healthy","Healthy Volunteer","Healthy Adult","Healthy Subjects","Healthy Volunteers Only","Healthy Non-smokers",[201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218],"Persea Americana","blood glucose","blood insulin","adiponectin","leptin","GLP-1","appetite","satiety","glucose tolerance","GIP","ghrelin","Peptide YY (PYY)","glucose metabolism","dietary fats","meal challenge","meal tolerance test","dietary fiber","glycemia","2025-03-24",{"date":178,"type":37},{"date":222,"type":22},"2025-03",{"date":224,"type":22},"2026-06",{"name":226,"class":85},"University of Vermont Medical Center",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":16,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":45},"100582774","effects-of-recreational-soccer-training-on-physical-fitness-and-gross-motor-coordination-in-prepubertal-boys-and-girls-100582774","NCT06867679","Effects of Recreational Soccer Training on Physical Fitness and Gross Motor Coordination in Prepubertal Boys and Girls","Inclusion Criteria:\n\n* Children between age 7 to9\n* Flamingo balance test between 11-14\n* Both genders\n\nExclusion Criteria:\n\n* Presence of any chronic medical condition\n* Children who areinvolved inother training program\n* Having any physical disability or impairment","7 Years","9 Years",{"count":236,"type":22},70,[57],"Physical activity is essential for the healthy development of children, contributing significantly to their physical fitness and motor skills. Prepubertal children experience changes in physical growth. During the prepubertal phase, engaging in regular physical activity can lead to substantial improvements in cardiovascular health, muscular strength, agility, and coordination. Physical fitness has been recognized as a key determinant in healthy lifestyles based increasingly on criteria referenced to general health. However, many children and adolescents are only exposed to vigorous physical activity during school based physical education classes. That way, schools seem to provide an excellent setting to enhance physical activity and physical fitness levels. Soccer, a widely popular sport, offers an engaging and enjoyable way for children to improve their physical fitness and gross motor coordination.\n\nThis study aims to investigate the effects of recreational soccer training on physical fitness and gross motor coordination in prepubertal boys and girls and to compare the effects of recreational soccer training between boys and girls. This current study will be a clinical trial; data will be calculated from Dar-e-Arqam School, upper mall Lahore. A total of 70 prepubertal children (35 boys and 35 girls) will be recruited for this study. Inclusion criteria for the study will be 7 to 9 years old boys and girls. participants should be in good general health, without any medical condition that could affect their ability to participate in physical activities. Individuals with physical disabilities or impairments that prevent them from engaging in soccer activities will be excluded. Participants will be divided into two experimental groups: Group A (boys) and Group B (girls). Both groups will undergo the same soccer training program. The soccer training program will consist of sessions held thrice a week for 8 weeks, each lasting 60 minutes.Outcomes to be analyzed will be Physical fitness and Gross motor coordination. Data collection will be done before and after the intervention. Tools used for data collection will be Physical fitness test battery for children to assess physical fitness and rohrer's index will be used to assess somatotype. Gross motor coordination will be evaluated using the Körperkoordinations test für Kinder (KTK) test battery. Data will be analyzed through SPSS version 26.00.",[28],[241],"Physical Fitness","2025-03-04",{"date":244,"type":37},"2025-03-10",{"date":246,"type":37},"2025-02-20",{"date":248,"type":22},"2025-07-30",{"name":250,"class":85},"Riphah International University",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":45},"100567180","blood-flow-restriction-bfr-training-on-the-ulnar-collateral-ligament-ucl-100567180","NCT06664827","Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)","Outcomes of Blood Flow Restriction Training on the Ulnar Collateral Ligament","Inclusion Criteria:\n\n* Healthy volunteer\n* Agree to complete all exercise sessions and program in its entirety\n* Between the ages of 18-50 years old\n\nExclusion Criteria:\n\n* Current or recent injury of the hand, elbow, or shoulder\n* Outside of the ages of 18-50 years old\n* Vascular compromise or previous vascular surgery\n* History of DVT\n* Current participation in other BFR research study\n* Currently participating in a structured strength training program\n* Any musculoskeletal conditions resulting in inability to exercise\n* Participants may not be collegiate\u002Fprofessional baseball\u002Fsoftball players\n* Vulnerable populations","50 Years",{"count":260,"type":22},50,[57],"The goal of this clinical trial is to identify any differences in elbow ulnar collateral ligament (UCL) relative thickness and joint space laxity in the dominant arm following an 8-week course of low intensity resistance exercises with blood flow restriction (BFR) exercises in healthy volunteers. The main questions it aims to answer are:\n\n1. Do BFR exercises contribute to a change in the relative ligament thickness of the UCL, and changes in the ulnohumeral joint space?\n2. Are there changes in arm strength following the 8-week strengthening protocol with\u002Fwithout BFR?\n\nParticipants will:\n\n* Complete two BFR sessions a week for a total of eight weeks.\n* Complete an exercise session with both arms (dominant arm will receive BFR) at each study visit.\n* Have sonographs taken of the UCL at the first and last study visit.\n* Complete strength assessments at the first and last study visit.",[194,28,74],"2025-01-21",{"date":266,"type":37},"2025-01-22",{"date":268,"type":37},"2025-01-16",{"date":270,"type":22},"2028-11",{"name":272,"class":85},"The Methodist Hospital Research Institute"]